EULAV Asset Management - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 152 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q1 2022. The put-call ratio across all filers is 0.68 and the average weighting 0.0%.

Quarter-by-quarter ownership
EULAV Asset Management ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q1 2023$2,618,850
+8.6%
195,0000.0%0.10%
-1.0%
Q4 2022$2,412,150
-56.2%
195,000
-50.6%
0.10%
-57.4%
Q3 2022$5,510,000
+1.0%
395,0000.0%0.24%
+8.4%
Q2 2022$5,455,000
-25.5%
395,000
-12.2%
0.22%
+3.2%
Q1 2022$7,322,000
-0.1%
450,0000.0%0.22%
+17.8%
Q4 2021$7,331,000
-25.2%
450,000
-31.8%
0.18%
-28.6%
Q3 2021$9,801,000
+46.5%
660,000
+97.0%
0.26%
+46.3%
Q2 2021$6,690,000
-13.5%
335,0000.0%0.18%
-14.5%
Q1 2021$7,732,000
-6.6%
335,0000.0%0.21%
-4.2%
Q4 2020$8,275,000
+32.2%
335,000
+121.9%
0.22%
+16.8%
Q3 2020$6,260,000
-13.5%
151,0000.0%0.18%
-21.9%
Q2 2020$7,234,000
-23.9%
151,0000.0%0.24%
-37.6%
Q1 2020$9,507,000
-54.1%
151,000
-9.6%
0.38%
-46.8%
Q4 2019$20,695,000
+58.3%
167,000
-15.2%
0.71%
+48.1%
Q3 2019$13,073,000
-16.6%
197,0000.0%0.48%
-18.0%
Q2 2019$15,675,000
-21.9%
197,000
+9.4%
0.59%
-28.9%
Q1 2019$20,070,000
+172.8%
180,000
+146.6%
0.83%
+124.7%
Q4 2018$7,358,000
-22.4%
73,000
-2.7%
0.37%
-9.4%
Q3 2018$9,477,000
+41.2%
75,000
-6.2%
0.41%
+31.4%
Q2 2018$6,713,000
+36.4%
80,0000.0%0.31%
+31.5%
Q1 2018$4,922,000
+27.6%
80,000
+21.2%
0.24%
+29.1%
Q4 2017$3,856,000
+0.7%
66,0000.0%0.18%
+0.6%
Q3 2017$3,831,000
-39.2%
66,000
+26.9%
0.18%
-41.4%
Q2 2017$6,296,000
+7.1%
52,0000.0%0.31%
+3.0%
Q1 2017$5,881,000
+17.7%
52,000
+13.0%
0.30%
+11.5%
Q4 2016$4,998,000
-34.0%
46,0000.0%0.27%
-32.9%
Q3 2016$7,571,000
+36.0%
46,000
+17.9%
0.40%
+31.5%
Q2 2016$5,565,000
+39.7%
39,000
+25.8%
0.30%
+37.4%
Q1 2016$3,983,000
-8.0%
31,000
+6.9%
0.22%
-6.3%
Q4 2015$4,331,000
-3.3%
29,000
+7.4%
0.24%
-7.1%
Q3 2015$4,478,000
-15.7%
27,000
+22.7%
0.26%
-8.6%
Q2 2015$5,310,000
+169.0%
22,000
+214.3%
0.28%
+173.5%
Q1 2015$1,974,0007,0000.10%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q1 2022
NameSharesValueWeighting ↓
Chicago Capital Management, LLC 185,781$4,611,56512.16%
Samsara BioCapital, LLC 640,688$11,878,3563.64%
ALPINE ASSOCIATES MANAGEMENT INC. 2,203,295$40,849,0892.14%
Versor Investments LP 378,480$7,017,0191.42%
Magnetar Financial LLC 2,407,209$44,629,6551.14%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 2,077,893$38,524,1360.85%
Fort Baker Capital Management LP 430,600$7,983,3240.74%
EHP Funds Inc. 84,210$1,561,2530.73%
Terrapin Asset Management, LLC 30,000$556,2000.63%
AQR Arbitrage LLC 734,970$13,626,3440.61%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders